Exemestane interactions
Full monograph for ExemestaneCheck it against another medicine
Medicines
256 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Drospirenone + Estetrol | Majorsource also lists Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Thalidomide | Major | Synergy | Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism… | 20 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Apalutamide | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Armodafinil | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Bosentan Monohydrate | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Brigatinib | Moderate | Metabolism | Coadministration with brigatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Brigatinib has been shown in… | 6 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Moderate | Metabolism · Unknown | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the…2 documented mechanisms | 11 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Cenobamate | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Moderate | Metabolism · Unknown | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the…2 documented mechanisms | 11 sources — open the full entry |
| Conjugated EstrogenCreamTablet | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Conjugated Estrogen + Bazedoxifene | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Cyproterone Acetate + Ethinyl Estradiol | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Deferasirox | Moderate | Metabolism | Coadministration with deferasirox may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism may involve… | 3 sources — open the full entry |
| Dexamethasone | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Dexamethasone + Levofloxacin | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acid | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Dexamethasone + Tobramycin | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Dienogest + Estradiol Valerate | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Drospirenone + Estradiol | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol0.02 mg0.03 mg | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Drospirenone + Ethinyl Estradiol + Levomefolate | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Efavirenz | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Elagolix Sodium | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Enzalutamide | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Estradiolbasevaginal cream | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Estradiol + Dydrogesterone | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Estradiol Hemihydrate + Progesterone Micronized | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Estradiol Valerate | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Ethinyl Estradiol + Desogestrel0.02 mg0.03 mg | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Ethinyl Estradiol + Gestodene | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Ethinyl Estradiol + Levonorgestrel + Ferrous Fumarate | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Ethinyl Estradiol + Lynestrenol0.0375 mg0.05 mg | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Fosphenytoin Sodium | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Griseofulvin [Ultra Microsize] | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Ivosidenib | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapine | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Lefamulin Acetate | Moderate | Metabolism | When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with… | 6 sources — open the full entry |
| Lorlatinib | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Mavacamten | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 1 sources — open the full entry |
| Medroxyprogesterone AcetateInjectionTablet | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Moxifloxacin Hydrochloride + Dexamethasone | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Norgestrel + Ethinyl Estradiol + Ferrous Fumarate | Moderate | Antagonism | Theoretically, estrogen-containing drugs may negate the pharmacologic effects of aromatase inhibitors in the treatment of hormone-dependent breast cancer… | 3 sources — open the full entry |
| Oxcarbazepine | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Phenobarbital | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
| Phenytoin Sodium | Moderate | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of exemestane, which is primarily metabolized by the… | 11 sources — open the full entry |
Conditions
Conditions in which Exemestane needs care, as documented in this source.
Osteoporosis
ModerateReductions in bone mineral density (BMD) over time are seen with the use of exemestane. Women with osteoporosis or at risk of osteoporosis should have their BMD formally assessed by densitometry at treatment initiation. Monitoring for BMD loss is recommended, and treatment for it should be started as appropriate.
1 source
- "Product Information. Aromasin (exemestane)." Pharmacia and Upjohn (2001):
Vitamin D Deficiency
ModerateRoutine assessment of vitamin D levels prior to the start of aromatase inhibitor treatment should be performed, due to the high prevalence of vitamin D deficiency in women with early breast cancer. Women with vitamin D deficiency should receive supplementation.
1 source
- "Product Information. Aromasin (exemestane)." Pharmacia and Upjohn (2001):